---
title: "Robustness of Path-Preservation Benchmarks for Dimensionality Reduction of Single-Cell Trajectories"
id: "biorxiv-20-evaluating-the-robustness-of-path-preservation-benchmarks-for-dimensionality"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-20-evaluating-the-robustness-of-path-preservation-benchmarks-for-dimensionality"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.09.01.748633v1?rss=1"
published_at: "2026-09-05T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Robustness of Path-Preservation Benchmarks for Dimensionality Reduction of Single-Cell Trajectories
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-20-evaluating-the-robustness-of-path-preservation-benchmarks-for-dimensionality
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.09.01.748633v1?rss=1)
- **Published At:** 2026-09-05T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study isolates the geometric effect of **dimensionality reduction** (DR) on known single-cell trajectories, independent of full trajectory inference pipelines. - Authors developed and tested a panel of twelve geometric **path-preservation** metrics on two datasets with ground-truth trajectories: a linear CD4+ T‑cell PC1 path (3,096 cells, 51 proteins) and a cyclic B‑cell cell‑cycle loop from CyTOF. - Sixteen DR methods were compared, including UMAP, MDS, TSNE, PHATE, CNPE, LPMIP, SPMDS, LPP, DVE, LAPEIG and others; metrics covered length, curvature, spatial similarity, Spearman correlations of distances and segment lengths, and structural complexity measures (self-intersection, coiling). - The reference-path density (fraction of cells used to define the path) was varied from 1% to 10% (31–310 path points) to test sensitivity of metric values and method rankings to point-density thresholds. - Absolute metric values changed smoothly with increasing path-density (wider reference bands), but composite method ranks aggregated across all twelve metrics remained stable across density thresholds for both linear and cyclic topologies. - A single discriminating metric, SpatDistSpear, separated DR methods into high-, mid-, and low-fidelity groups; its separation was density-independent though its top-tier differed from the composite rank. - Top-performing methods across densities on the linear path included **UMAP, MDS, CNPE, TSNE, SPE, LPMIP**; consistently low performers included SPMDS, LPP, DVE, LAPEIG, PHATE. - On the cyclic loop the same density-independence held, with largely conserved best and worst performers (CNPE, LPMIP, SPE, MDS as good; LAPEIG, DVE, SPMDS as poor), though UMAP and TSNE fell from top on the linear path to mid-tier on the loop, indicating topology-dependent ranking. - Key conclusion: DR-induced distortion of trajectory geometry can be benchmarked independently; within-dataset rank stability supports using a fixed reference-path threshold, but rankings do not necessarily transfer across trajectory shapes. - The authors declare no competing interests.
## Clinical Analysis & Structured Key Points
Motivation: Comparative studies of trajectory inference (TI) methods evaluate complete computational pipelines, making it impossible to isolate how much distortion is introduced specifically by the dimensionality reduction (DR) step. To our knowledge, no study has directly and systematically evaluated how well DR methods alone preserve a known reference path when projecting high-dimensional single-cell data to two dimensions, and no current study has introduced a dedicated set of metrics to quantify the degree of path-preservation quality after dimensionality reduction. This gap matters because DR is a universal preprocessing choice that shapes all downstream trajectory analysis, yet its independent geometric effect on path structure remains uncharacterized, and practitioners have no principled way to quantify it. Methods: We tested a panel of candidate path-preservation metrics on two single-cell datasets with known reference trajectories, one linear and one cyclic, to determine whether the resulting metric values, DR-method rankings, and overall conclusions are sensitive to the number of points used to construct and display the path, and whether they remain stable once that choice is fixed. The primary linear dataset is a CD4+ T-cell surface-protein dataset (3,096 cells, 51 proteins); a ground-truth reference path was constructed from cells lying close to the first principal component (PC1) of a single cluster, providing a known linear trajectory in the high-dimensional space. Sixteen DR methods were applied and twelve geometric path-preservation metrics were computed, spanning log-ratio distortions of length, curvature, and spatial similarity; Spearman rank correlations of pairwise distances and segment lengths; and structural complexity measures including self-intersection frequency and coiling. To test the sensitivity of this evaluation framework to path density, we varied the fraction of cells used to define the reference path from 1% to 10% (31-310 path points) and tracked how method rankings responded. The same analysis was repeated on a topologically distinct reference, a closed B-cell cell-cycle loop detected by persistent homology in a separate CyTOF dataset, to test whether these conclusions about metric and method stability hold for cyclic as well as linear trajectories. Results: The central sensitivity question, whether the number of points used to construct the reference path changes the evaluation's conclusions, was answered negatively on both datasets. On the linear PC1 trajectory, absolute values of all twelve metrics shifted smoothly as the path-density threshold was varied from 1% to 10% (31-310 points), reflecting the broadening of the reference band, but each method's composite rank remained stable across every threshold: no method changed performance tier as the hyperparameter varied. A composite rank aggregating all twelve metrics identified the same consistently high-performing methods (UMAP, MDS, CNPE, TSNE, SPE, LPMIP) and consistently low-performing methods (SPMDS, LPP, DVE, LAPEIG, PHATE) at every density level tested. Considered on its own, `SpatDistSpear`, the single most discriminating metric, separated a high-fidelity group (LPMIP, DM, MDS, SPMDS, DVE, CISOMAP, CNPE; all r > 0.80) from a mid-range group (LAPEIG, SPE, PHATE, UMAP, TSNE, FOSMOD) and a low-fidelity group (PFA, NNP, LPP); global distance preservation and overall composite performance therefore do not always agree on the same "top tier" of methods, but this disagreement in which metric identifies the best methods is itself density-independent rather than an artifact of the specific threshold chosen. The cyclic loop reproduced the same density-independence: absolute metric values drifted with the per-segment band width, yet each method's composite rank again held constant across all eleven density levels. The identity of the best and worst performers was largely, though not entirely, conserved between the two topologies, with CNPE, LPMIP, SPE, and MDS as top performers and LAPEIG, DVE, and SPMDS as poor performers on both the linear path and the closed loop. UMAP and TSNE were exceptions, dropping from top performers on the linear path to the middle of the sixteen-method panel, rather than the worst tier, on the closed loop. This topology-dependence is a property of the reference geometry rather than of path density: it holds consistently regardless of how many points are used to define the path. Significance: This work introduces a direct, pipeline-independent evaluation of how DR methods distort trajectory geometry, a benchmarking dimension absent from existing TI comparisons. The within-dataset rank stability result, demonstrated on both a linear and a cyclic reference trajectory, validates the use of a fixed reference-path threshold as a robust operating point for large-scale DR benchmarking; however, the partial reordering of top performers between topologies shows that a method's DR benchmark ranking is trajectory-shape-dependent and should not be assumed to transfer from a linear to a cyclic reference.
## Related Clinical Research

- [Fathers' perinatal mental health needs: qualitative insights from North East England and North Cum](https://medichelpline.com/clinical-feed/bmj-open-6-understanding-fathers-perinatal-mental-health-and-well-being-support-needs-a.md)
- [Standardised Patient Teaching and Medical Students' Clinical Reasoning: Systematic Review Protocol](https://medichelpline.com/clinical-feed/bmj-open-1-impact-of-the-standardised-patient-teaching-method-on-medical-students-clinical.md)
- [Post-occupancy evaluation of former residences of celebrities in Yangzhou using online reviews and](https://medichelpline.com/clinical-feed/plos-one-2-post-occupancy-evaluation-of-former-residences-of-celebrities-in-yangzhou-based.md)
- [Kurort Health Walking in a Forest: Short-Term Physiological and Psychological Effects](https://medichelpline.com/clinical-feed/plos-one-3-physiological-and-psychological-outcomes-of-a-community-based-kurort-health.md)
- [Methylation shapes vertebrate dinucleotide composition: CpG depletion and AG/CT enrichment across](https://medichelpline.com/clinical-feed/biorxiv-0-five-hundred-million-years-of-methylation-tracing-the-mutational-origins-of.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.